Ezetimibe Added to Statin Furthers Plaque Regression by IVUSEzetimibe Added to Statin Furthers Plaque Regression by IVUS
The findings "could lead to an early reevaluation of the new ACC/AHA lipid-management guidelines that endorse statins as the only recommended drugs for treating cholesterol-related CV risk," researchers say. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 30, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
A promising new treatment for high triglycerides
When you think about fat circulating in the bloodstream, you might immediately think of cholesterol. But there’s another type of fat you shouldn’t ignore: triglycerides. As with cholesterol, high triglycerides can also increase the risk of having a heart attack. Existing drugs for lowering triglycerides aren’t that good at reducing heart attack risk. That’s why a report on a new way to lower triglycerides, published in today’s New England Journal of Medicine, is generating some excitement among cardiologists.
What are triglycerides?
Triglycerides are a type of fat that circulates in the bloods...
Source: New Harvard Health Information - July 29, 2015 Category: Consumer Health News Authors: Gregory Curfman, MD Tags: Heart Health high triglycerides Source Type: news
Studies support broader use of cholesterol-lowering statins
The latest guidelines used to determine who should take a cholesterol-lowering statin to prevent heart disease appear to be more accurate and cost-efficient than the previous guidelines. That’s according to two studies led by Harvard researchers, both published in this week’s Journal of the American Medical Association.
For many years, the main deciding factor in who needed to take a statin was the level of an individual’s harmful low-density lipoprotein cholesterol (LDL). Updated guidelines published in 2013 by the American College of Cardiology and the American Heart Association moved away from LDL and ...
Source: New Harvard Health Information - July 16, 2015 Category: Consumer Health News Authors: Julie Corliss Tags: Drugs and Supplements cholesterol high cholesterol statins Source Type: news
No Benefit from Ezetimibe in NASH (CME/CE)
(MedPage Today) -- Drug did not reduce liver fat or improve liver histology. (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - June 15, 2015 Category: Gastroenterology Source Type: news
Ezetimibe or Statin? The Impact of IMPROVE-IT
(MedPage Today) -- Final results are published; should they alter practice? (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 7, 2015 Category: Cardiology Source Type: news
Combination of a cholesterol-lowering statin and ezetimibe lowers risk of a heart attack or stroke
High cholesterol is a key culprit in the development of cardiovascular disease, the leading cause of death in the United States and many other developed countries. We know that lowering cholesterol helps prevent heart attacks and strokes. But an unanswered question remains: how low should you go? New research published online today in The New England Journal of Medicine suggests that lower is better.
Cholesterol and cardiovascular disease
Cholesterol travels through the bloodstream in two main particles: high-density lipoprotein (HDL) and low-density lipoprotein (LDL). HDL scavenges cholesterol from the bloodstream and fro...
Source: New Harvard Health Information - June 4, 2015 Category: Consumer Health News Authors: Gregory Curfman, MD Tags: Drugs and Supplements Heart Health cholesterol ezetimibe Source Type: news
Some Improvement in Post-ACS Outcomes with Adjunctive Ezetimibe (FREE)
By Harlan M. Krumholz, MD, SM
Dr. Krumholz is Editor-in-Chief of NEJM Journal Watch Cardiology, from which this story was adapted. See full coverage at the link below.Ezetimibe plus simvastatin is associated with better outcomes at 7 years than statin monotherapy, according to a New England … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 4, 2015 Category: Primary Care Source Type: news
IMPROVE-IT Published: Ezetimibe Lowers LDL, Reduces EventsIMPROVE-IT Published: Ezetimibe Lowers LDL, Reduces Events
In an editorial, two experts argue IMPROVE-IT supports the LDL-cholesterol-lowering hypothesis—that lower LDL, regardless of how it is achieved, is better—and that there's nothing uniquely beneficial about ezetimibe. Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 3, 2015 Category: Cardiology Tags: Cardiology News Source Type: news
Results from Investigational IMPROVE-IT Study of VYTORIN® (ezetimibe and simvastatin) Published in the New England Journal of Medicine
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK),
known as MSD outside the United States and Canada, today announced that
the New England Journal of Medicine published the results
of the IMPROVE-IT trial, an investigational study comparing treatment
with VYTORIN® (ezetimibe and simvastatin) to treatment with
simvastatin alone in more than 18,000 patients presenting with acute
coronary syndromes.
Language:
English
Co...
Source: Merck.com - Product News - June 3, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
How Marketing And Media Muddled The Truth About The Heart Drug Vytorin
Over the past eight years I’ve written more than 100 stories criticizing a drug called ezetimibe, which is sold by itself under the brand name Zetia and in combination with an older drug under the brand Vytorin. When I started off, in 2006, it was just “the Vytorin question:” did these (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 17, 2015 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
New Analysis from Investigational IMPROVE-IT Study Shows VYTORIN® (ezetimibe/simvastatin) Reduced Total (Initial and Recurrent) Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes
Dateline City:
SAN DIEGO
SAN DIEGO--(BUSINESS WIRE)--Merck (NYSE:MRK),
known as MSD outside the United States and Canada, today announced
results from a pre-specified exploratory analysis of the investigational
IMPROVE-IT study of more than 18,000 patients presenting with acute
coronary syndromes.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestor...
Source: Merck.com - Product News - March 16, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Alirocumab Subcutaneously as Monotherapy vs EzetimibeAlirocumab Subcutaneously as Monotherapy vs Ezetimibe
Will a bi-weekly injection be what saves the day for patients with hypercholesterolemia? Future Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 5, 2015 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
New Data from IMPROVE-IT Study of VYTORIN® (ezetimibe/simvastatin) and TRA 2ºP TIMI 50 Study of ZONTIVITY® (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions
Dateline City:
KENILWORTH, N.J.
Investigational data from IMPROVE-IT to be announced in Featured Clinical Research Session II
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that new data from two trials of the company’s
cardiovascular medicines will be presented at the 2015 American College
of Cardiology Annual Scientific Sessions (ACC.15), March 14-16 in San
Diego.
Language:
...
Source: Merck.com - Product News - February 25, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
IMPROVE-IT: Are We Back to 'The Lower the Better' for LDL-C?IMPROVE-IT: Are We Back to 'The Lower the Better' for LDL-C?
Seth Bilazarian and Chris Cannon discuss the role of ezetimibe in secondary prevention and whether super-low LDL-C levels are the way to go. theheart.org on Medscape (Source: theHeart.org)
Source: theHeart.org - December 1, 2014 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Friday Feedback: Will IMPROVE-IT Trial Affect Primary Care?
(MedPage Today) -- Study cast ezetimibe plus statin in a new light. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 21, 2014 Category: Cardiology Source Type: news
